Navigation Links
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP,by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it was informed late Wednesday, March 07, 2007, by the Department of Health & Human Services (HHS) that NEUMUNE(R), the Company's product candidate for the treatment of Acute Radiation Syndrome (ARS) was found technically unacceptable and was no longer in the competitive range for the Request for Proposal (RFP) No. DHHS-ORDC-DDA-05-12 entitled, "Medical Countermeasures to Mitigate or Treat Neutropenia Alone or in Combination with Co-Morbidities Associated with Acute Radiation Syndrome (ARS)." No other rationale was provided. Further, Hollis-Eden was notified that HHS had cancelled the solicitation in its entirety.

The Company was surprised by this decision by HHS. In June 2006, based on HHS' evaluation of the Company's technical and cost proposal, HHS informed the Company that its proposal for NEUMUNE was within the competitive range. HHS reaffirmed this decision in October 2006, and Hollis-Eden believes that as of that time its proposal was the only proposal still being considered by HHS. Since that time, HHS has not requested any additional safety or efficacy data on NEUMUNE that had not previously been provided in detailed or summary form. Therefore, the Company is unable to comprehend how NEUMUNE can no longer meet the technical requirements of the solicitation.

"Given the nature and stage of our communications with HHS regarding our original ARS proposal and subsequent revisions, this decision by HHS to exclude our proposal and cancel the RFP is shocking and difficult to understand," stated Richard B. Hollis, Chairman and Chief Executive Officer of Hollis-Eden. "While we will attempt to gain a better understanding from HHS why this determination was made, we clearly met all of the very detailed requirements of the solicitation. NEUMUNE is the only agent ever to have shown the ability to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:10/17/2014)... THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ ... appointment of R. Sanders Williams , M.D., president ... L. Mahley Distinguished Professor.  "We are ... the Amgen Board," said Robert A. Bradway , ... deep and distinguished experience in academic medicine and his ...
(Date:10/17/2014)... , October 17, 2014 ... Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced the ... : North American Automated External Defibrillators ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report North ... analyzes the market of devices based ...
(Date:10/17/2014)... 2014  UBM Medica US announces that Endocrinology ... other clinicians who treat patients with type 2 ... use of insulin .  Nearly all ... therapy – daily injections of one or more ... the function of pancreatic beta cells. Insulin is a ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... SUNNYVALE, Calif., Feb. 28, 2011 /PRNewswire/ ... company developing innovative technologies in diabetes management, announced that ... Silicon Valley Bank and ... used to help complete clinical trials and commercialize POGO™, ...
... Feb. 28, 2011 Advanced Cell Diagnostics, Inc. ... study utilizing RNAscope™ technology to detect human papillomavirus ... head and neck cancer. HPV status determined by ... patient outcome and highly concordant with that determined ...
Cached Medicine Technology:Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... , ST. LOUIS, Aug. 24 ... herbicide Atrazine have attorney and clean water advocate Steve Tillery ... and accountability for the herbicide,s manufacturers. , , ... the New York Times and the Peoria Journal Star have ...
... , , , OAKLAND, ... LATINA Style magazine on the publication,s list of the 50 ... , The LATINA Style survey, now in ... the value of diversity in the workplace, and identifies the corporations in ...
... Institute of Allergy and Infectious Diseases (NIAID), a component ... applications for a new initiative to establish a consortium ... these cooperative centerswhich together will receive funding up to ... immune system under normal conditions and to understand how ...
... - Concussions, whether from an accident, sporting event, or ... mental processes. Scientists have debated for centuries whether concussions ... changes that merely impair the way brain cells function, ... at Albert Einstein College of Medicine of Yeshiva University ...
... State University study shows that invigorated and dedicated employees ... home life. K-State psychology researchers studied how positive ... interactions. They found that employees who are engaged in ... dedication and absorption in daily activities, have better moods ...
... , SWARTZ CREEK, Mich., Aug. ... Health Services Division is partnering with CareSource in Ohio to ... outcomes and reduce healthcare costs associated with the disease. As ... is focused on the early identification and treatment of their ...
Cached Medicine News:Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 2Health News:Korein Tillery: Is Time Running Out for the Manufacturers of the Herbicide Atrazine? 3Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 2Health News:Kaiser Permanente Named 2009 Company of the Year by LATINA Style Magazine 3Health News:NIAID to fund new human immune profiling research centers 2Health News:Strong link found between concussions and brain tissue injury 2Health News:Strong link found between concussions and brain tissue injury 3Health News:Researchers find that employees who are engaged in their work have happier home life 2Health News:Diplomat Specialty Pharmacy Partners With CareSource -- Launches Chronic Kidney Disease Management Program with Ohio Plan 2
... -4C. 5.5 Cubic Ft. ... light. Manual push button ... Two shelves. In-door shelves ... thermostat. Magnetic gasket. Hermetically ...
Designed to meet the requirements of reagent grade water for routine analysis....
... Needs, Synergy systems produce ultrapure water from pre-treated ... 1.2 L/min to meet the basic needs of ... dual-wavelength UV lamp (185 nm and 254 nm) ... contaminants (< 5 ppb TOC when fed by ...
... mechanism for speed, stability and durability. ... display modes, multiple units of measure, ... auto print, and GLP/GMP/ISO output including ... clock. Touch-key calibration with external weights ...
Medicine Products: